You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Patent: 10,213,420


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,213,420
Title:Combination therapy for treatment of HBV infections
Abstract: Provided herein is a combination therapy comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog. The combination therapy is useful for the treatment of HBV infection. Also provided herein are compositions comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog.
Inventor(s): Hartman; George D. (Lansdale, PA)
Assignee: NOVIRA THERAPEUTICS, INC. (Doylestown, PA)
Application Number:15/284,807
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Understanding the Patent Landscape: A Comprehensive Analysis of US Patent 10,213,420

Introduction

Patent law in the United States is a complex and evolving field, influenced by legislative changes, judicial decisions, and updates from the United States Patent and Trademark Office (USPTO). This article provides a detailed analysis of the claims and the broader patent landscape, using US Patent 10,213,420 as a case study.

Patent Eligibility Under Section 101

To begin with, any patent analysis must consider the eligibility of the subject matter under Section 101 of the Patent Act. This section defines what types of inventions can be patented, excluding abstract ideas, laws of nature, and natural phenomena unless they are integrated into a practical application[5].

The Alice/Mayo Test

The Supreme Court's decisions in Alice Corp. v. CLS Bank International and Mayo Collaborative Services v. Prometheus Laboratories established a two-step test to determine patent eligibility. First, it must be determined if the claims are directed to an ineligible concept. If so, the second step assesses whether the claims contain an inventive concept that transforms the nature of the claim into a patent-eligible application[5].

Practical Applications and Technological Improvements

The 2024 USPTO guidance update on AI patents emphasizes the importance of practical applications and technological improvements. For a claim to be patent-eligible, it must integrate a judicial exception into a practical application, imposing meaningful limits on the exception. This is illustrated by examples where claims that specify the use of abstract ideas in real-world applications, such as enhancing speech recognition systems, are considered patent-eligible[2].

Continuation Procedures and Patent Allowance Rates

Understanding the complexities of the patent examination process is crucial. Continuation procedures, such as continuations, continuations-in-part, and divisional applications, can significantly impact the calculation of patent allowance rates. These procedures allow applicants to introduce new subject matter or separate claimed inventions, complicating the tracking of progenitor applications and their outcomes[1].

Advanced Patent Searching Techniques

Comprehensive patent searching is essential for navigating the patent landscape. This involves understanding the scope and coverage of related patents within a family, considering multi-jurisdiction filing, indexing inconsistencies, language barriers, and scientific sophistication. Claims variation during the prosecution process can also affect the validity and scope of patents[3].

Case Study: US Patent 10,213,420

While the specific details of US Patent 10,213,420 are not provided here, a critical analysis would involve several key steps:

Claim Analysis

  • Subject Matter Eligibility: Determine if the claims are directed to an ineligible concept under Section 101. If so, assess whether the claims contain an inventive concept that transforms the nature of the claim.
  • Practical Applications: Evaluate whether the claims specify real-world applications that provide concrete benefits or solve specific problems in the relevant field.

Prosecution History

  • Review the prosecution history to understand any amendments or narrowing of claims during the examination process. This can impact the scope and validity of the patent.
  • Identify any continuation procedures that may have been used, as these can affect the allowance rate and the overall patent family.

Technological Contributions

  • Assess whether the patent claims offer a concrete technological improvement. This involves evaluating if the claimed invention integrates abstract ideas into practical applications, providing tangible benefits.

Industry Expert Insights

Industry experts often highlight the importance of demonstrating real-world applications and technological improvements. For example, in the context of AI patents, the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself and whether it shows significant human contribution and practical utility[2].

Statistical Context

The probability of receiving a US patent varies based on several factors, including the technology field and the entity size of the applicant. For instance, data from the USPTO shows that between 1996 and 2005, the family allowance rate, which includes the outcomes of continuation applications, was a critical metric for understanding the overall success rate of patent applications[1].

Challenges and Considerations

  • Complexity of Examination Process: The patent examination process is complicated by factors such as continuation procedures and the alteration of claims during examination.
  • Judicial Exceptions: Claims must navigate judicial exceptions to ensure they are not directed to abstract ideas, laws of nature, or natural phenomena without an inventive concept.
  • Global Patent Landscape: The patent landscape is influenced by multi-jurisdiction filing and inconsistencies in indexing across databases, which can complicate comprehensive patent searches[3].

Key Takeaways

  • Patent Eligibility: Ensure that claims are directed to patent-eligible subject matter and integrate judicial exceptions into practical applications.
  • Prosecution History: Understand the prosecution history, including any continuation procedures and claim amendments.
  • Technological Contributions: Demonstrate concrete technological improvements and real-world applications.
  • Advanced Searching: Utilize advanced patent searching techniques to navigate the complexities of the patent landscape.
  • Industry Insights: Consider industry expert insights on demonstrating practical utility and significant human contribution.

FAQs

  1. What is the significance of the Alice/Mayo test in patent eligibility?

    • The Alice/Mayo test is a two-step process to determine if a patent claim is eligible under Section 101. It checks if the claim is directed to an ineligible concept and if it contains an inventive concept that transforms the claim into a patent-eligible application[5].
  2. How do continuation procedures affect patent allowance rates?

    • Continuation procedures can complicate the calculation of patent allowance rates by allowing applicants to introduce new subject matter or separate claimed inventions, resulting in multiple patents from a single progenitor application[1].
  3. What is the importance of practical applications in AI patent eligibility?

    • Practical applications are crucial for AI patent eligibility. Claims must specify real-world applications that provide concrete benefits or solve specific problems in the relevant field to be considered patent-eligible[2].
  4. How does the USPTO's 2024 guidance update impact AI patents?

    • The update clarifies that AI-assisted inventions are evaluated on equal footing with other technologies, focusing on whether the claimed invention integrates a judicial exception into a practical application and provides meaningful limits on the exception[2].
  5. What are the challenges in conducting comprehensive patent searches?

    • Comprehensive patent searches are challenging due to multi-jurisdiction filing, inconsistencies in indexing, language barriers, and the scientific sophistication of innovations. Claims variation during prosecution also complicates these searches[3].

Sources

  1. Carley, M., & Hegde, D. (n.d.). What Is the Probability of Receiving a US Patent?. The Yale Journal of Law & Technology.
  2. Mintz. (2024, July 25). Understanding the 2024 USPTO Guidance Update on AI Patent. Mintz Insights.
  3. CAS. (2023, July 24). Advanced patent searching techniques. CAS Insights.
  4. PubChem. (n.d.). N- (arylalkyl) - 1h- indole- 2 - sulfonic acid amide compounds and their therapeutic use as cannabinoid allosteric modulators. PubChem.
  5. Congressional Research Service. (2024, December 4). Patent-Eligible Subject Matter Reform: An Overview. CRS Reports.

More… ↓

⤷  Subscribe

Details for Patent 10,213,420

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Biogen Inc. AVONEX interferon beta-1a For Injection 103628 May 17, 1996 ⤷  Subscribe 2034-02-05
Biogen Inc. AVONEX interferon beta-1a Injection 103628 May 28, 2003 ⤷  Subscribe 2034-02-05
Biogen Inc. AVONEX interferon beta-1a Injection 103628 February 27, 2012 ⤷  Subscribe 2034-02-05
Kadmon Pharmaceuticals Llc INFERGEN interferon alfacon-1 Injection 103663 October 06, 1997 ⤷  Subscribe 2034-02-05
Emd Serono, Inc. REBIF interferon beta-1a Injection 103780 March 07, 2002 ⤷  Subscribe 2034-02-05
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.